Incyte/$INCY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Ticker

$INCY
Primary listing

Industry

Biotechnology

Employees

2,617

ISIN

US45337C1027

Incyte Metrics

BasicAdvanced
$13B
696.21
$0.10
0.90
-

What the Analysts think about Incyte

Analyst ratings (Buy, Hold, Sell) for Incyte stock.

Bulls say / Bears say

Incyte raised its 2024 sales forecast for Jakafi to between $2.74 billion and $2.77 billion, reflecting strong demand across multiple indications. (reuters.com)
Opzelura's sales surged by 52% to $139 million in Q3 2024, indicating robust market adoption and potential for future growth. (reuters.com)
Incyte's strategic collaboration with Genesis Therapeutics to develop novel small molecule medicines using AI could enhance its drug discovery capabilities and pipeline diversity. (stocktitan.net)
Insider selling activity, including the sale of 6,043 shares by EVP Vijay K. Iyengar, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Analysts have issued mixed ratings, with Cantor Fitzgerald maintaining a 'neutral' stance, suggesting potential uncertainty about Incyte's growth prospects. (americanbankingnews.com)
Increased R&D and SG&A expenses have contributed to an earnings miss in Q4 2024, raising concerns about the company's cost management and profitability. (monexa.ai)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

Incyte Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Incyte Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INCY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs